Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units

Mao Hagihara, Hidefumi Kasai, Takumi Umemura, Takahiro Kato, Takaaki Hasegawa, Hiroshige Mikamo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Severely ill patients in intensive care units (ICU) are frequently at risk of developing fungal infections. Itraconazole (ITCZ), a triazole antifungal agent, is used for the treatment of aspergillosis, candidiasis, and cryptoccosis. The present retrospective pharmacokinetic-pharmacodynamic (PK-PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients. All of the patients admitted to Aichi Medical University Hospital ICU in 2008 who were treated with ITCZ injections for fungal infections were included in the study. After outcomes had been classified as cure or failure, a PK-PD analysis was performed. In addition, the probability of PD target attainment was assessed using a Monte Carlo simulation. Ten patients were enrolled in the study. Satisfactory outcomes were obtained in 4 of the 10 patients. No significant differences in the area under the 24-h curve (AUC 0-24), peak concentrations and trough concentrations were observed between the two groups. However, it was observed that the higher the AUC 0-24, the better the outcome. Moreover, our results showed that additional dosage is needed to attain a sufficiently high AUC0-24/MIC in about 20% of patients. Our retrospective study is the first to show that it is important to consider the host's condition when ITCZ is administered, especially in ICU patients. The present findings are also useful for optimizing the individual dosage of ITCZ based on AUC0-4 for the treatment of patients infected with Candida spp.

Original languageEnglish
Pages (from-to)224-230
Number of pages7
JournalJournal of Infection and Chemotherapy
Volume17
Issue number2
DOIs
Publication statusPublished - 2011 Apr
Externally publishedYes

Fingerprint

Itraconazole
Mycoses
Intensive Care Units
Pharmacokinetics
Area Under Curve
Triazoles
Aspergillosis
Candidiasis
Antifungal Agents
Candida
Retrospective Studies
Injections
Therapeutics

Keywords

  • Candida
  • Itraconazole
  • Pharmacokinetics-pharmacodynamics (PK-PD)

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. / Hagihara, Mao; Kasai, Hidefumi; Umemura, Takumi; Kato, Takahiro; Hasegawa, Takaaki; Mikamo, Hiroshige.

In: Journal of Infection and Chemotherapy, Vol. 17, No. 2, 04.2011, p. 224-230.

Research output: Contribution to journalArticle

Hagihara, Mao ; Kasai, Hidefumi ; Umemura, Takumi ; Kato, Takahiro ; Hasegawa, Takaaki ; Mikamo, Hiroshige. / Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. In: Journal of Infection and Chemotherapy. 2011 ; Vol. 17, No. 2. pp. 224-230.
@article{31f93538f7ef4a8aaa57dcd868c7e2e4,
title = "Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units",
abstract = "Severely ill patients in intensive care units (ICU) are frequently at risk of developing fungal infections. Itraconazole (ITCZ), a triazole antifungal agent, is used for the treatment of aspergillosis, candidiasis, and cryptoccosis. The present retrospective pharmacokinetic-pharmacodynamic (PK-PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients. All of the patients admitted to Aichi Medical University Hospital ICU in 2008 who were treated with ITCZ injections for fungal infections were included in the study. After outcomes had been classified as cure or failure, a PK-PD analysis was performed. In addition, the probability of PD target attainment was assessed using a Monte Carlo simulation. Ten patients were enrolled in the study. Satisfactory outcomes were obtained in 4 of the 10 patients. No significant differences in the area under the 24-h curve (AUC 0-24), peak concentrations and trough concentrations were observed between the two groups. However, it was observed that the higher the AUC 0-24, the better the outcome. Moreover, our results showed that additional dosage is needed to attain a sufficiently high AUC0-24/MIC in about 20{\%} of patients. Our retrospective study is the first to show that it is important to consider the host's condition when ITCZ is administered, especially in ICU patients. The present findings are also useful for optimizing the individual dosage of ITCZ based on AUC0-4 for the treatment of patients infected with Candida spp.",
keywords = "Candida, Itraconazole, Pharmacokinetics-pharmacodynamics (PK-PD)",
author = "Mao Hagihara and Hidefumi Kasai and Takumi Umemura and Takahiro Kato and Takaaki Hasegawa and Hiroshige Mikamo",
year = "2011",
month = "4",
doi = "10.1007/s10156-010-0102-4",
language = "English",
volume = "17",
pages = "224--230",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units

AU - Hagihara, Mao

AU - Kasai, Hidefumi

AU - Umemura, Takumi

AU - Kato, Takahiro

AU - Hasegawa, Takaaki

AU - Mikamo, Hiroshige

PY - 2011/4

Y1 - 2011/4

N2 - Severely ill patients in intensive care units (ICU) are frequently at risk of developing fungal infections. Itraconazole (ITCZ), a triazole antifungal agent, is used for the treatment of aspergillosis, candidiasis, and cryptoccosis. The present retrospective pharmacokinetic-pharmacodynamic (PK-PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients. All of the patients admitted to Aichi Medical University Hospital ICU in 2008 who were treated with ITCZ injections for fungal infections were included in the study. After outcomes had been classified as cure or failure, a PK-PD analysis was performed. In addition, the probability of PD target attainment was assessed using a Monte Carlo simulation. Ten patients were enrolled in the study. Satisfactory outcomes were obtained in 4 of the 10 patients. No significant differences in the area under the 24-h curve (AUC 0-24), peak concentrations and trough concentrations were observed between the two groups. However, it was observed that the higher the AUC 0-24, the better the outcome. Moreover, our results showed that additional dosage is needed to attain a sufficiently high AUC0-24/MIC in about 20% of patients. Our retrospective study is the first to show that it is important to consider the host's condition when ITCZ is administered, especially in ICU patients. The present findings are also useful for optimizing the individual dosage of ITCZ based on AUC0-4 for the treatment of patients infected with Candida spp.

AB - Severely ill patients in intensive care units (ICU) are frequently at risk of developing fungal infections. Itraconazole (ITCZ), a triazole antifungal agent, is used for the treatment of aspergillosis, candidiasis, and cryptoccosis. The present retrospective pharmacokinetic-pharmacodynamic (PK-PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients. All of the patients admitted to Aichi Medical University Hospital ICU in 2008 who were treated with ITCZ injections for fungal infections were included in the study. After outcomes had been classified as cure or failure, a PK-PD analysis was performed. In addition, the probability of PD target attainment was assessed using a Monte Carlo simulation. Ten patients were enrolled in the study. Satisfactory outcomes were obtained in 4 of the 10 patients. No significant differences in the area under the 24-h curve (AUC 0-24), peak concentrations and trough concentrations were observed between the two groups. However, it was observed that the higher the AUC 0-24, the better the outcome. Moreover, our results showed that additional dosage is needed to attain a sufficiently high AUC0-24/MIC in about 20% of patients. Our retrospective study is the first to show that it is important to consider the host's condition when ITCZ is administered, especially in ICU patients. The present findings are also useful for optimizing the individual dosage of ITCZ based on AUC0-4 for the treatment of patients infected with Candida spp.

KW - Candida

KW - Itraconazole

KW - Pharmacokinetics-pharmacodynamics (PK-PD)

UR - http://www.scopus.com/inward/record.url?scp=79955902959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955902959&partnerID=8YFLogxK

U2 - 10.1007/s10156-010-0102-4

DO - 10.1007/s10156-010-0102-4

M3 - Article

C2 - 20799049

AN - SCOPUS:79955902959

VL - 17

SP - 224

EP - 230

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 2

ER -